[go: up one dir, main page]

WO2024116198A1 - Formulation liquide orale d'empagliflozine ou de son sel pharmaceutiquement acceptable - Google Patents

Formulation liquide orale d'empagliflozine ou de son sel pharmaceutiquement acceptable Download PDF

Info

Publication number
WO2024116198A1
WO2024116198A1 PCT/IN2023/051096 IN2023051096W WO2024116198A1 WO 2024116198 A1 WO2024116198 A1 WO 2024116198A1 IN 2023051096 W IN2023051096 W IN 2023051096W WO 2024116198 A1 WO2024116198 A1 WO 2024116198A1
Authority
WO
WIPO (PCT)
Prior art keywords
liquid formulation
pharmaceutically acceptable
empagliflozin
solution
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2023/051096
Other languages
English (en)
Inventor
Girish Shantilal Achliya
Piyush Kishor Mundada
Mayur Dilip KAPADIA
Dipak Rameshbhai Faldu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syri Research Private Ltd
Original Assignee
Syri Research Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syri Research Private Ltd filed Critical Syri Research Private Ltd
Publication of WO2024116198A1 publication Critical patent/WO2024116198A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Definitions

  • the present invention relates to a liquid formulation comprising Empagliflozin or its pharmaceutically acceptable salt thereof.
  • the present invention is more particularly related to an oral liquid formulation comprising Empagliflozin or its pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable excipient.
  • This invention also related to a process for preparing the liquid formulation and its application in the treatment of type 2 diabetes mellitus, symptomatic chronic heart failure and chronic kidney disease.
  • Type 2 diabetes mellitus is a chronic, progressive metabolic condition that is not fully understood. Hyperglycemia represents the primary characteristic of diabetes mellitus, which is a chronic, progressive and inadequately understood metabolic disorder. Type 2 diabetes mellitus (T2DM) which encompasses a range of conditions, initially arising from tissue insulin resistance and gradually advances to a state characterized by the complete loss of secretory activity in the beta cells of the pancreas. It is believed to result from impaired insulin secretion, insulin resistance in tissues, or a combination of both factors.
  • sulfonylureas like glipizide, glyburide, gliclazide, and glimepiride
  • meglitinides like repaglinide and nateglinide
  • biguanides like metformin
  • thiazolidinediones such as rosiglitazone and pioglitazone
  • a-glucosidase inhibitors like acarbose, miglitol, and voglibose
  • DPP-4 inhibitors like sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin, or combinations thereof.
  • Sodium glucose co-transporter-2 (SGLT2) inhibitors are relatively new additions to the class of antidiabetic agents.
  • the SGLT2 inhibitors are recognised for glycemic control and have reduced the risk of kidney disease for those with diabetes and can reduce the risk of being hospitalized or dying from heart failure.
  • Empagliflozin is a widely recognized SGLT2 inhibitor that has received approval in the United State (USA) and Europe for its use in enhancing glycemic control among adults with type 2 diabetes mellitus (T2DM).
  • T2DM type 2 diabetes mellitus
  • These drugs reduce plasma glucose (PG) levels by decreasing the renal threshold for glucose excretion (RTG) and inhibiting renal glucose reabsorption, leading to an increase in urinary glucose excretion (UGE).
  • the IUPAC name of Empagliflozin is (lS)-l,5-anhydro-l-(4-chloro-3- ⁇ 4-[(3S)- tetrahydrofuran-3-yloxy]benzyl ⁇ phenyl)-D-glucitol and has the following structure:
  • Empagliflozin is a white to yellowish non-hygroscopic crystalline solid; it is chiral, possesses 6 stereogenic centres and a single polymorphic form has been observed.
  • the patent US7579449B2 discloses Empagliflozin, or the stereoisomers thereof, the mixtures thereof and the salts thereof generically and specifically.
  • the invention further relates to pharmaceutical compositions and the use for preparing a pharmaceutical composition for the treatment of metabolic disorders.
  • the patent US7713938B2 discloses a crystalline form of Empagliflozin having an X-ray diffraction pattern, to a method for the preparation and use thereof for preparing medicaments.
  • the patent US9949997B2 discloses a method to reduce the risk of cardiovascular death in a patient with type 2 diabetes mellitus comprising administering Empagliflozin to the patient, wherein Empagliflozin is administered orally in a total daily amount of 10 mg or 25 mg.
  • the patent application CN112618495 A discloses Empagliflozin dry suspension and a preparation method thereof.
  • the Empagliflozin dry suspension is prepared from the components in percentage by weight: 1-10% of Empagliflozin, 55-80% of filler, 10-20% of a suspending aid, 0.1-2% of a lubricant, 8-15% of a disintegrating agent and 0.05-1% of a flavoring agent.
  • the Empagliflozin is classified under the biopharmaceutics classification system (BCS) class III due to its characteristics of high solubility but low permeability.
  • BCS biopharmaceutics classification system
  • the inventors of the present invention solved the problems associated with extemporaneous preparation and the challenges in dose adjustment.
  • the present invention provides simple manufacturing process, enhances patient compliance by offering acceptable taste-masking, improved drug solubility and enhanced stability.
  • the present invention provides a liquid formulation comprising Empagliflozin or its pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable excipient.
  • the present invention provides a liquid formulation comprising Empagliflozin or its pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable excipient, wherein the liquid formulation is suitable for oral administration.
  • the present invention provides a liquid formulation comprising Empagliflozin or its pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable excipient, wherein Empagliflozin or its pharmaceutically acceptable salt thereof is present at a concentration of 0.1 to 10% w/v in the liquid formulation.
  • the present invention provides the liquid formulation comprising Empagliflozin or its pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable excipient, wherein the liquid formulations is in the form of suspension or solution or the like.
  • the present invention provides the liquid formulation comprising Empagliflozin or its pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable excipient, wherein the liquid formulation has a pH ranging from about 4 to about 8.
  • the present invention provides the liquid formulation comprising Empagliflozin or its pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable excipient, wherein the liquid formulation is stable under storage conditions of 25°C/60% RH, 30°C/65% RH, 40°C/75% RH, and/or 2-8°C.
  • the present invention provides a liquid formulation comprising: a) 0.1-10% w/v of Empagliflozin or its pharmaceutically acceptable salt thereof; b) 0.015-3% w/v of a preservative; c) 0.01-10% w/v of a viscosity enhancer or viscosity enhancing agent; d) 0.5-15% w/v of a solubilizer or solubilizing agent; and e) one or more pharmaceutically acceptable excipient, wherein the liquid formulation has a pH ranging from about 4 to about 8.
  • the present invention provides a liquid formulation comprising: a) 0.1-10% w/v of Empagliflozin or its pharmaceutically acceptable salt thereof; b) 0.015-3% w/v of a preservative; c) 0.01-10% w/v of a viscosity enhancer or viscosity enhancing agent; and d) one or more pharmaceutically acceptable excipient, wherein the liquid formulation has a pH ranging from about 4 to about 8.
  • the present invention provides a process for the preparation of a liquid formulation, comprising: a) separately taking part quantity of vehicle in beaker, heating and adding preservative and dissolving to get clear solution and cool; b) adding slowly solubilizing agent and dissolving in another part of vehicle, stirring to get clear solution; c) adding slowly Empagliflozin and dissolving in above solution of step b) and mixing using stirrer to get clear solution; d) adding and dissolving viscosity enhancer in above solution of step c) and mixing using stirrer to get clear solution; e) adding solution of step d) in solution of step a) using stirring to get clear solution; f) adding sweetener in above solution using stirring to get clear solution; g) adding flavour in above solution using stirring to get clear solution; and h) making up the volume with vehicle and mixing using stirrer to get clear solution.
  • the present invention provides a process for the preparation of a liquid formulation, comprising: a) adding preservatives into vehicle under continue stirring for desired time to get clear solution; b) soaking viscosity enhancer into vehicle and keep for desired time; c) adding soaked viscosity enhancer of step-b) into step-a) solution under homogenizer for desired time and speed; d) adding Empagliflozin into step-c) solution under homogenizer for desired time and speed; e) adding sweetener and mixing flavour into step-d) under homogenizer for desired time; f) making up final volume of step-e) suspension with vehicle and homogenizing for desired time and speed; and g) recording pH of step-f) suspension and adjusting pH with buffering agents.
  • the present invention provides the liquid formulation comprising Empagliflozin or its pharmaceutically acceptable salt with one or more pharmaceutically acceptable excipient for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy, also used for the treatment of symptomatic chronic heart failure and chronic kidney disease.
  • Empagliflozin as used herein is not limited to the Empagliflozin, but includes its solvates, hydrates, solvate-hydrate, all pharmaceutically acceptable salts, esters, amides, isomers and stereo isomers and polymorphic form including amorphous form.
  • terapéuticaally effective amount is defined to mean the amount or quantity of the active drug (e.g. Empagliflozin or a pharmaceutical acceptable salt thereof), which is sufficient to elicit an appreciable biological response when administered to the patient.
  • active drug e.g. Empagliflozin or a pharmaceutical acceptable salt thereof
  • formulation or “composition” or “pharmaceutical composition” or “dosage form” or “liquid formulation” or “liquid pharmaceutical composition” as used herein synonymously include dosage forms such as solution, suspension and the like.
  • excipient or “excipients” or “ingredient” means a pharmacologically inactive component that are useful in preparing a liquid formulation which are generally safe, nontoxic and are acceptable for human pharmaceutical use.
  • stable or “stability” encompass any characteristic of the liquid formulation which may be affected by storage conditions including, without limitation, potency, total impurities, degradation products, specific optical rotation, optical purity, appearance, viscosity and colour and clarity.
  • the storage conditions which may affect stability include, for example, duration of storage, temperature, humidity, and/or light exposure.
  • the Empagliflozin may be present in the form of a pharmaceutically acceptable salt.
  • Pharmaceutically acceptable salts include, without being restricted thereto hydrochloric acid, sulfuric acid, phosphoric acid, oxalic acid, acetic acid, citric acid, malic acid, benzoic acid, maleic acid, fumaric acid, tartaric acid, succinic acid, glutamic acid, methanesulfonic acid and p-toluenesulfonic acid.
  • the present invention relates to a liquid formulation comprising Empagliflozin or its pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable excipient.
  • the present invention relates to a liquid formulation comprising Empagliflozin or its pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable excipient, wherein the liquid formulation is suitable for oral administration.
  • the present invention relates to the liquid formulation comprising Empagliflozin or its pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable excipient, wherein Empagliflozin or its pharmaceutically acceptable salt thereof is present at a concentration of 0.1 to 10% w/v in the liquid formulation.
  • the present invention relates to the liquid formulation comprising Empagliflozin or its pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable excipient, wherein the liquid formulations is in the form of solution or suspension or the like.
  • the present invention relates to the liquid formulation comprising Empagliflozin or its pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable excipient, wherein the liquid formulations is in the form of solution.
  • the present invention relates to the liquid formulation comprising Empagliflozin or its pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable excipient, wherein the liquid formulations is in the form of suspension.
  • the present invention relates to the liquid formulation comprising Empagliflozin or its pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable excipient, wherein the liquid formulation has a pH ranging from about 4 to about 8 with a particularly preferred range of about 4.5 to about 7.5.
  • the pH of the liquid formulation can be adjusted to a pH of about 4, about 4.5, about 5, about 5.5, about 6, about 6.5 or about 7 or about 7.5 or about 8.
  • the present invention relates to the liquid formulation comprising Empagliflozin or its pharmaceutically acceptable salt with one or more pharmaceutically acceptable excipient, wherein the liquid formulation is stable for at least one month under storage conditions of 25°C/60% RH, 30°C/65% RH, 40°C/75% RH, and/or 2-8°C.
  • the one or more pharmaceutically acceptable excipient which are selected from the group consisting of preservatives, viscosity enhancers or viscosity enhancing agents, solubilizers or solubilizing agents, buffers or buffering agents, sweeteners or sweetening agents, flavors or flavours, vehicles/solvents, wetting agents, cosolvents, suspending agents, antifoaming agents, taste masking agents, antioxidants, chelating agents, stabilizers, colorants and any other excipient known to the art for making liquid formulations.
  • compositions are the components that are added to the liquid formulation other than the active ingredient Empagliflozin or pharmaceutically acceptable salt thereof. Excipient may be added to facilitate manufacture, enhance stability, enhance product characteristics, enhance patient acceptability etc.
  • preservatives include but not limited to group comprising parabens (p-hydroxybenzoate) including methyl p-hydroxybenzoate (methylparaben or MHB), ethyl p-hydroxybenzoate (ethylparaben), propyl p- hydroxybenzoate (propylparaben) and butyl p-hydroxybenzoate (butylparaben) and their salts such as sodium methyl parahydroxybenzoate (Sodium MHB), sodium propyl parahydroxybenzoate (Sodium PHB),
  • Other suitable preservatives include sorbic acid, sodium sorbate, potassium sorbate, calcium sorbate, benzoic acid, sodium benzoate, potassium benzoate, calcium benzoate, sodium citrate, butylated hydroxyl toluene (BHT), butylated hydroxyl anisole (BHA), halogenated diphenyl ether (e.g.
  • the preferred preservative is methyl p-hydroxybenzoate (MHB), sodium benzoate and sorbic acid.
  • the preservatives are present in an amount of about 0.001% w/v to about 4% w/v of the liquid formulation. Particularly, the preservative is present in an amount of about 0.015 % w/v to about 3% w/v of the liquid formulation.
  • viscosity enhancers or viscosity enhancing agents include but not limited to group comprising of glycerol, polyethylene glycol, polyethylene oxide, dextrin, liquid maltitol, liquid sorbitol, cellulose derivatives such as hydroxy ethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methylcellulose, carboxymethyl cellulose and its salts/derivatives e.g., carboxymethyl cellulose sodium (carmellose sodium), microcrystalline cellulose, microcrystalline cellulose and carboxymethyl cellulose sodium, carbomers, gums such as xanthan gum, locust bean gum, tragacanth gum, pectin, propylene glycol alginate, gelatin, pectin, alginates, starches, chitosan, povidone, copovidone, polyvinyl compounds, sugar alcohols, colloidal silica; maltodextrin, starch; and mixtures thereof.
  • glycerol poly
  • the preferred viscosity enhancer or viscosity enhancing agents are carboxymethyl cellulose sodium (carmellose sodium).
  • the viscosity enhancers are present in an amount of about 0.01 to about 15% w/v of the liquid formulation. Particularly, the viscosity enhancers are present in an amount of about 0.015% to about 12% w/v of the liquid formulation. More particularly, the viscosity enhancers are present in an amount of about 0.1% to about 10% w/v of the liquid formulation.
  • solubilizers or solubilizing agents include but not limited to group comprising glycol, acetone, alcohol (ethanol), benzyl alcohol, benzyl benzoate, butylene glycol, dibutyl phthalate, sorbitol, poloxamer, polysorbates, polyoxyethylene fatty acid esters, sodium lauryl sulphate, diethyl phthalate, dimethyl phthalate, dimethyl sulfoxide, dimethylacetamide, glycofurol, glycerin, isopropyl alcohol, isopropyl myristate, isopropyl palmitate, propylene glycol, polyethylene glycol, propylene carbonate, pyrrolidone, triacetin, triethyl citrate and triolein, the cyclodextrin includes a- cyclodextrin, P-cyclodextrin, 6-cyclodextrin, y-cyclodextrin, or combinations thereof,
  • substituted cyclodextrins include hydroxypropyl-P-cyclodextrin (HP-P-CD) and sulfobutylether-P-cyclodextrin (SBE-P-CD), and the like.
  • the preferred solubilizers are hydroxypropyl-P-cyclodextrin (HP-P-CD).
  • the solubilizers are present in an amount of about 0.01% to about 40% w/v of the liquid formulation. Particularly, the solubilizers are present in an amount of about 0.1% to about 20% w/v of the liquid formulation. More particularly, the solubilizers are present in an amount of about 0.5% to about 15% w/v of the liquid formulation.
  • buffering agents or buffers include but not limited to group comprising sodium dihydrogen phosphate, sodium bicarbonate, potassium bicarbonate, magnesium hydroxide, magnesium lactate, magnesium gluconate, aluminum hydroxide, aluminum hydroxide/sodium bicarbonate precipitate, citric acid, sodium citrate, sodium tartarate, sodium acetate, sodium carbonate, sodium polyphosphate, potassium polyphosphate, sodium pyrophosphate, potassium pyrophosphate, disodium hydrogenphosphate, trisodium phosphate, tripotassium phosphate, sodium acetate, potassium metaphosphate, magnesium oxide, magnesium carbonate, magnesium silicate, calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, and other calcium salts and/or combinations thereof.
  • the preferred Buffering agent is sodium dihydrogen phosphate.
  • sweeteners or sweetening agents include but not limited to group comprising sucralose, glucose, maltose, sucrose, aspartame, mannitol, sorbitol, xylitol, acesulfame, neotame, stevia, dextrose, saccharin, saccharin sodium, mannose, glycerol or glycerin and/or combinations thereof.
  • the preferred sweetener is sucralose.
  • sweetener is present in an amount of from about 0.01 to about 20% w/v, more preferably from about 0.1 to 3% w/v of the liquid formulation.
  • flavouring agents or flavours according to the present invention include but not limited to group comprising mix fruit flavour, grapefruit, orange, lime, lemon, mandarin, pineapple, strawberry, raspberry, mango, passion fruit, kiwi, apple, pear, peach, apricot, cherry, grapes, banana, spearmint, peppermint, eucalyptus, and/or combinations thereof, the preferred flavour is mix fruit flavour.
  • vehicles or solvents according to the present invention include but not limited to group comprising water, propylene glycol, dipropylene glycol, polypropylene glycol, ethylene glycol, polyethylene glycol, glycerin, butylene glycol, hexylene glycol, polyoxyethylene, and/or combinations thereof.
  • antioxidants include but not limited to group comprising butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl gallate, vitamin E, hydroquinone, hydroxycoumarins, ethanolamine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, thiodipropionic acid and its esters, and dithiocarbamates and/or combinations thereof.
  • BHT butylated hydroxytoluene
  • BHA butylated hydroxyanisole
  • propyl gallate vitamin E
  • hydroquinone hydroxycoumarins
  • ethanolamine lecithin
  • cephalin ascorbic acid
  • malic acid malic acid
  • sorbitol phosphoric acid
  • thiodipropionic acid and its esters and dithiocarbamates and/or combinations thereof.
  • chelating agents include but not limited to group comprising disodium edentate salt (EDTA), tartaric acid, malic acid, citric acid and/or combinations thereof.
  • EDTA disodium edentate salt
  • colorants include but are not limited to caramel colorant, red colorant Enocianin, Indigo yellow, Quinoline yellow, Quinizarine Green, FD&C Blue #1 Aluminum Lake, FD&C Blue #2, other FD&C Blue colors, titanium dioxide, iron oxide and/or combinations thereof.
  • the storage conditions used in the present invention are 25°C/60% RH and/or 30°C/65% RH and/or 40°C/75% and/or 2-8°C.
  • the ‘storage condition of 25°C/60% RH’ means storage at a temperature of 25 °C and 60% relative humidity.
  • the ‘storage condition of 30°C/65% RH’ means storage at a temperature of 30°C and 65% relative humidity
  • the ‘storage condition of 40°C/75% RH’ means storage at a temperature of 40°C and 75% relative humidity.
  • the ‘storage condition of 2- 8 °C’ means storage at a temperature of 2 to 8°C.
  • the liquid formulation is stable for at least two months under storage conditions of 25°C/60% RH, 30°C/65% RH, 40°C/75% RH, and/or 2-8°C.
  • the present invention relates to a liquid formulation
  • a liquid formulation comprising: a) 0.1-10% w/v of Empagliflozin or its pharmaceutically acceptable salt thereof; b) 0.015-3% w/v of a preservative; c) 0.1-10% w/v of a viscosity enhancer or viscosity enhancing agent; d) 0.5-15% w/v of a solubilizer or solubilizing agent; and e) one or more pharmaceutically acceptable excipient, wherein the liquid formulation has a pH ranging from about 4 to about 8.
  • the present invention relates to a liquid formulation
  • a liquid formulation comprising: a) 0.1-10% w/v of Empagliflozin or its pharmaceutically acceptable salt thereof; b) 0.015-3% w/v of a preservative; c) 0.1-10% w/v of a viscosity enhancer or viscosity enhancing agent; and d) one or more pharmaceutically acceptable excipient, wherein the liquid formulation has a pH ranging from about 4 to about 8.
  • the present invention relates to a process for the preparation of a liquid formulation, comprising: a) separately taking part quantity of vehicle in beaker, heating and adding preservative and dissolving to get clear solution and cool; b) adding slowly solubilizing agent and dissolving in another part of vehicle, stirring to get clear solution; c) adding slowly Empagliflozin and dissolving in above solution of step b) and mixing using stirrer to get clear solution; d) adding and dissolving viscosity enhancer in above solution of step c) and mixing using stirrer to get clear solution; e) adding solution of step d) in solution of step a) using stirring to get clear solution; f) adding sweetener in above solution using stirring to get clear solution; g) adding flavour in above solution using stirring to get clear solution; and h) making up the volume with vehicle and mixing using stirrer to get clear solution.
  • the present invention relates to a process for the preparation of a liquid formulation, comprising: a) adding preservatives into vehicle under continue stirring for desired time to get clear solution; b) soaking viscosity enhancer into vehicle and keep for desired time; c) adding soaked viscosity enhancer of step-b) into step-a) solution under homogenizer for desired time and speed; d) adding Empagliflozin into step-c) solution under homogenizer for desired time and speed; e) adding sweetener and mixing flavour into step-d) under homogenizer for desired time; f) making up final volume of step-e) suspension with vehicle and homogenizing for desired time and speed; and g) recording pH of step-f) suspension and adjusting pH with buffering agents.
  • the present invention relates to the liquid formulation that comprising Empagliflozin or its pharmaceutically acceptable salt with one or more pharmaceutically acceptable excipient for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy, also used for the treatment of symptomatic chronic heart failure and chronic kidney disease.
  • the present invention relates to the liquid formulation that comprising Empagliflozin or its pharmaceutically acceptable salt with one or more pharmaceutically acceptable excipient that enhances patient compliance by providing acceptable taste-masking, improves drug solubility and storage stability.
  • the liquid formulation can be conveniently packaged in various pharmaceutically acceptable containers, such as bottles, depending on the required dosage form.
  • Empagliflozin 10mg/5ml Oral Solution Manufacturing Process: a) separately taken part quantity of water in a beaker, heated to a temperature range of 80- 90°C, methyl parahydroxybenzoate, sodium benzoate and sorbic acid were added and dissolved to get a clear solution and allowed to cool up to 40°C; b) hydroxypropyl beta-cyclodextrin was slowly added and dissolved in another portion of water using a stirrer at a speed of 1500 - 2500 RPM for 30 minutes to get a clear solution; c) Empagliflozin was slowly added and dissolved to the above solution and mixed using stirrer at the speed of 1500 - 2500 RPM for 30 minutes to get clear solution; d) carmellose sodium was added and dissolved in the above solution, and the mixture is stirred using a stirrer at a speed of 1500 - 2500 RPM for 30 minutes to get clear solution; e) step-d) solution was added to the step-a) solution using

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une formulation liquide comprenant de l'empagliflozine ou son sel pharmaceutiquement acceptable avec un ou plusieurs excipients pharmaceutiquement acceptables, son procédé de préparation et son application dans le traitement du diabète sucré de type 2, de l'insuffisance cardiaque chronique symptomatique et de la maladie rénale chronique.
PCT/IN2023/051096 2022-12-02 2023-11-25 Formulation liquide orale d'empagliflozine ou de son sel pharmaceutiquement acceptable Ceased WO2024116198A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202221069611 2022-12-02
IN202221069611 2022-12-02

Publications (1)

Publication Number Publication Date
WO2024116198A1 true WO2024116198A1 (fr) 2024-06-06

Family

ID=91323215

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2023/051096 Ceased WO2024116198A1 (fr) 2022-12-02 2023-11-25 Formulation liquide orale d'empagliflozine ou de son sel pharmaceutiquement acceptable

Country Status (1)

Country Link
WO (1) WO2024116198A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017032799A1 (fr) * 2015-08-27 2017-03-02 Boehringer Ingelheim Vetmedica Gmbh Compositions pharmaceutiques liquides comprenant des inhibiteurs de sglt-2
US20200069713A1 (en) * 2009-02-13 2020-03-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20200237794A1 (en) * 2014-04-01 2020-07-30 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
US20230381101A1 (en) * 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200069713A1 (en) * 2009-02-13 2020-03-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20200237794A1 (en) * 2014-04-01 2020-07-30 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
WO2017032799A1 (fr) * 2015-08-27 2017-03-02 Boehringer Ingelheim Vetmedica Gmbh Compositions pharmaceutiques liquides comprenant des inhibiteurs de sglt-2
US20230381101A1 (en) * 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors

Similar Documents

Publication Publication Date Title
US6806256B2 (en) Taste masked liquid pharmaceutical compositions
KR101490721B1 (ko) 감칠맛을 가진 디페리프론용 액상 제제
US10137114B2 (en) Rifaximin ready-to-use suspension
US20090048344A1 (en) Pharmaceutical composition comprising 5-methyl-2-2' (chloro-6'-fluoroanilino phe nylacetic acid
US20240374516A1 (en) Ready to use oral pharmaceutical suspension of dasatinib
US20110123631A1 (en) Oral compositions of clindamycin
WO2024116195A1 (fr) Formulation liquide à administration orale comprenant de la dapagliflozine ou son sel pharmaceutiquement acceptable
US20220016025A1 (en) Formulations of nebivolol
WO2024116198A1 (fr) Formulation liquide orale d'empagliflozine ou de son sel pharmaceutiquement acceptable
CA2417258A1 (fr) Systeme d'aromatisation pour compositions pharmaceutiques et procedes de fabrication de telles compositions
US20060100271A1 (en) Stabilized aqueous ranitidine compositions
WO2024116202A1 (fr) Formulation liquide à administration par voie orale de canagliflozine ou de son sel pharmaceutiquement acceptable
LU103368B1 (en) Pharmaceutical suspension of nilotinib
CA3147900A1 (fr) Composition pharmaceutique de temozolomide
US20050136116A1 (en) Stabilized prednisolone sodium phosphate solutions
WO2024144482A1 (fr) Compositions pharmaceutiques de suspension orale comprenant de l'acide chénodésoxycholique (cdca) en tant que principe actif et d'autres excipients pertinents
HK1152871B (en) Liquid formulation for deferiprone with palatable taste
SG190579A1 (en) Liquid formulation for deferiprone with palatable taste

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23897067

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23897067

Country of ref document: EP

Kind code of ref document: A1